
|Videos|June 30, 2022
Dr. Tian Zhang discusses tivozanib for advanced kidney cancer
Author(s)Urology Times staff
Tivozanib (Fotivda) is approved by the FDA for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma who have received 2 or more prior systemic therapies.
Advertisement
Tian Zhang, MD, associate professor at UT Southwestern Medical Center, discusses the FDA-approved therapy tivozanib (Fotivda) for patients with relapsed or refractory advanced renal cell carcinoma, including ongoing trials further exploring the agent.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men
2
Experts urge FDA to revisit labeling for testosterone replacement therapy in men
3
FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC
4
FDA approves zoliflodacin for uncomplicated urogenital gonorrhea
5


















